GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Intrinsic Value: Projected FCF

Deep Medicine Acquisition (Deep Medicine Acquisition) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-02), Deep Medicine Acquisition's Intrinsic Value: Projected FCF is $0.00. The stock price of Deep Medicine Acquisition is $3.20. Therefore, Deep Medicine Acquisition's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Deep Medicine Acquisition's Intrinsic Value: Projected FCF or its related term are showing as below:

DMAQ's Price-to-Projected-FCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.87
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Deep Medicine Acquisition Intrinsic Value: Projected FCF Historical Data

The historical data trend for Deep Medicine Acquisition's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Intrinsic Value: Projected FCF Chart

Deep Medicine Acquisition Annual Data
Trend Mar21 Mar22 Mar23
Intrinsic Value: Projected FCF
- - -

Deep Medicine Acquisition Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Deep Medicine Acquisition's Intrinsic Value: Projected FCF

For the Shell Companies subindustry, Deep Medicine Acquisition's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deep Medicine Acquisition's Price-to-Projected-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's Price-to-Projected-FCF falls into.



Deep Medicine Acquisition Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Deep Medicine Acquisition  (NAS:DMAQ) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Deep Medicine Acquisition's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.20/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deep Medicine Acquisition Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
595 Madison Avenue, 12th Floor, New York, NY, USA, 10017
Website
Deep Medicine Acquisition Corp is a blank check company.
Executives
John Chiang director 3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen director, officer: Chief Executive Officer C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo officer: Chief Financial Officer 40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc 10 percent owner 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017

Deep Medicine Acquisition (Deep Medicine Acquisition) Headlines

From GuruFocus

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By Value_Insider Value_Insider 10-24-2022

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By GlobeNewswire GlobeNewswire 10-24-2022